A5051591723- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Angiogenesis and VEGF in Cancer
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Renal cell carcinoma treatment
- Cancer Mechanisms and Therapy
- Hepatitis B Virus Studies
- Retinal Diseases and Treatments
- Epigenetics and DNA Methylation
- Pancreatic and Hepatic Oncology Research
- Mesenchymal stem cell research
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Microbial Inactivation Methods
- Liver physiology and pathology
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- RNA modifications and cancer
- Retinal Development and Disorders
- Gallbladder and Bile Duct Disorders
- MRI in cancer diagnosis
- Organ Transplantation Techniques and Outcomes
- Hepatitis C virus research
First Affiliated Hospital Zhejiang University
2016-2025
Southwest University
2022-2025
Beijing Anzhen Hospital
2020-2025
Capital Medical University
2020-2025
Zhejiang University
2015-2024
Wenzhou Medical University
2024
First Affiliated Hospital of Wenzhou Medical University
2024
Shandong University of Technology
2024
Shanghai Clinical Research Center
2020-2023
Peking University Cancer Hospital
2023
PURPOSE Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to compare clinical outcomes of LEN combined transarterial chemoembolization (LEN-TACE) versus monotherapy in HCC. MATERIALS AND METHODS This was multicenter, randomized, open-label, parallel group, phase III trial. Patients primary treatment-naive or initial recurrent HCC after surgery were randomly assigned (1:1)...
Abstract There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It necessary to investigate the therapeutic efficacy safety of TACE combined with PD-(L)1 inhibitors MTT real-world situations. In this nationwide, retrospective, cohort study, 826 HCC patients receiving either plus blockades (combination group, n = 376) or monotherapy...
Abstract Objectives This study aimed to investigate the efficacy and safety of transarterial chemoembolization (TACE) plus camrelizumab, a monoclonal antibody targeting programmed death-1, apatinib for patients with intermediate advanced hepatocellular carcinoma (HCC) in real-world setting. Methods A total 586 HCC treated either TACE camrelizumab (combination group, n = 107) or monotherapy (monotherapy 479) were included retrospectively. Propensity score matching analysis was used match...
For patients with sentinel lymph node (SLN) metastasis and low risk of residual non-SLN (NSLN) metastasis, axillary (ALN) dissection could lead to overtreatment. This study aimed develop validate an automated preoperative deep learning-based tool predict the SLN NSLN in breast cancer (BC) using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) images.In this machine learning study, we retrospectively enrolled 988 women BC from three hospitals Zhejiang, China between June 1, 2013...
Tumor-associated macrophages (TAMs) are a promising therapeutic target for cancers, but achieving multitarget therapy of TAMs is still challenging. Here, we develop protein-crowned micelle system targeted and synergistic TAM reprogramming to enhance cancer treatment. The doxorubicin-loaded micelles with hemoglobin crown (Hb-DOXM) can bind endogenous plasma haptoglobin realize specific M2-type targeting. Under the tumor hypoxic acidic environments, Hb-DOXM responsively release O2 DOX reduce...
Giant hepatic hemangioma is a benign liver condition that may be treated using surgery. We studied the digital subtraction angiographic (DSA) characteristics of giant hemangioma, and effectiveness transcatheter arterial embolization (TAE) alone for its treatment. This was retrospective study 27 patients diagnosed with TAE (using lipiodol mixed pingyangmycin) at Division Hepatobiliary Pancreatic Surgery, First Affiliated Hospital, Zhejiang University, between January 2010 March 2013. The...
This study aimed to investigate the efficacy and safety of drug eluting beads transarterial chemoembolization (DEB-TACE) treatment by CalliSpheres® in Chinese patients with hepatocellular carcinoma (HCC) as well predicting factors for response. 99 HCC were consecutively enrolled this study. All participants treated DEB-TACE. Clinical response was evaluated according modified Response Evaluation Criteria Solid Tumors (mRECIST) criteria. Common Terminology Adverse Events (CTCAE) used assess...
Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare clinical outcomes of lenvatinib plus drug-eluting beads transarterial chemoembolization (DEB-TACE) versus alone in real-world practice.This retrospective analysis included 142 consecutive patients who received DEB-TACE and 69 as from 15 Chinese academic centers November 2018 2019. Overall survival (OS), progression-free (PFS), objective response rate (ORR) were evaluated by modified...
Background and aims: Many patients with HCC of Barcelona Clinic Liver Cancer (BCLC) stage A exceeding the Milan criteria, or BCLC B, can undergo resection after successful preoperative therapy, but an optimal approach has not been identified. We investigated drug-eluting bead transarterial chemoembolization (DEB-TACE) plus sintilimab, in this setting. Approach Results: In prospective, phase II study (NCT04174781), adults ineligible for surgical resection, received sintilimab 200 mg DEB-TACE....
Breast cancer bone metastasis has become a common type that still lacks an effective treatment method. Although epigenetic drugs have demonstrated promise in therapy, their nontargeted accumulation and drug resistance remain nonnegligible limiting factors. Herein, we first found icaritin had strong synergistic effect with (JQ1) the suppression of breast cancer, which could help to relieve JQ1. To improve tumor-targeted efficacy, developed hypoxia-cleavable, RGD peptide-modified...
Treatment strategy for hepatocellular carcinoma (HCC) and Vp4 [main trunk] portal vein tumor thrombosis (PVTT) remains limited due to posttreatment liver failure. We aimed assess the efficacy of irradiation stent placement with 125 I plus transcatheter arterial chemoembolization (TACE) (ISP-TACE) compared sorafenib TACE (Sora-TACE) in these patients.In this multicenter randomized controlled trial, participants HCC PVTT without extrahepatic metastases were enrolled from November 2018 July...
To develop and validate a deep learning-based overall survival (OS) prediction model in patients with hepatocellular carcinoma (HCC) treated transarterial chemoembolization (TACE) plus sorafenib.This retrospective multicenter study consisted of 201 treatment-naïve, unresectable HCC who were TACE sorafenib. Data from 120 used as the training set for development. A learning signature was constructed using image features preoperative contrast-enhanced computed tomography images. An integrated...
Background and AimsTo validate prognostic performance of the China liver cancer (CNLC) staging system as well to compare these parameters with those Barcelona Clinic Liver Cancer (BCLC) for Chinese hepatocellular carcinoma (HCC) treated transarterial chemoembolization (TACE).
Abstract Purpose While the role of drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC) is established, questions regarding appropriate bead size use in patients remain. This trial evaluated effectiveness and safety DEB-TACE using small-size (≤ 100 μm) microspheres loaded with epirubicin. Materials Methods prospective, single-arm, multicenter study enrolled diagnosed HCC who underwent 40 (range, 30–50), 75 60–90), or 75–125) μm epirubicin-loaded...
Abstract Irreversible electroporation (IRE) with microsecond-pulsed electric fields (μsPEFs) can effectively ablate hepatocellular carcinomas in animal models. This preclinical study evaluates the feasibility and safety of IRE on porcine livers. Altogether, 10 pigs were included. Computed tomography (CT) was used to guide two-needle electrodes that inserted near hilus hepatis gall bladder. Animals followed-up at 2 hours 2, 7 14 days post-treatment. During after μsPEF ablation,...
After severe liver injury, biliary epithelial cells (BECs) undergo dedifferentiation into bipotential progenitor (BPPCs), which subsequently redifferentiate nascent hepatocytes and BECs to accomplish regeneration. However, the critical factors governing redifferentiation process of BPPCs remain largely unknown. Here, using a zebrafish model we observed specific expression khdrbs1a khdrbs1b (collectively known as khdrbs1) in through single-cell RNA analyses fluorescence situ hybridization....
Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter StudyLei Zhang, MD1, Jun-Hui Sun, MD, PhD2, Jian-Song Ji, PhD3, Bin-Yan Zhong, PhD1, Guan-Hui Zhou, MD2, Jing-Jing Song, MD3, Zhong-Heng Hou, Peng Huang, Shen Zhi Li, Xiao-Li Zhu, PhD1 Cai-Fang Ni, PhD1Audio Available | Share